Here are the 10-K annual reports from Hologic Inc (HOLX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow HOLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HOLX filings page.
Hologic, Inc. filed an amended annual report to add detailed Part III disclosures on directors, executive officers, governance and 2025 executive pay. The filing explains a performance‑heavy compensation program built around base salary, annual cash bonuses tied to adjusted revenue and adjusted EPS, and long‑term equity awards split among performance stock units, restricted stock units and stock options.
For fiscal 2025, short‑term incentives paid out at 76% of target based on adjusted revenue of $4.063 billion and adjusted EPS of $4.33. Performance stock units based on adjusted free cash flow, adjusted return on invested capital and relative total shareholder return vested between 100% and 200% of target, reflecting three‑year performance. The filing also details how outstanding equity awards and new cash retention bonuses for several named executives will be treated in connection with a pending merger at $76.00–$79.00 per share, including accelerated vesting, cash payments and contingent value rights.
Hologic, Inc. filed its Annual Report on Form 10-K and disclosed a definitive agreement to be acquired by funds managed by Blackstone and TPG. The buyers will acquire all outstanding Hologic shares for $76.00 per share in cash, plus a non-tradable contingent value right (CVR) of up to $3.00 per share in cash, for total potential consideration of $79.00 per share. The CVR payments depend on achieving specified global revenue metrics in the Breast Health business in fiscal 2026 and 2027, and the transaction is expected to close in the first half of calendar 2026, subject to stockholder approval and regulatory and other customary conditions.
Hologic describes four main segments—Diagnostics, Breast Health, GYN Surgical and Skeletal Health—focused on women’s health through early detection and treatment. As of March 29, 2025, the aggregate market value of common stock held by non-affiliates was $13,566,017,923, and as of November 13, 2025, there were 222,905,228 common shares outstanding.